{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T09:02:59Z","timestamp":1785488579310,"version":"3.56.0"},"reference-count":12,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1093\/ndt\/gfag159","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T11:31:02Z","timestamp":1783337462000},"source":"Crossref","is-referenced-by-count":0,"title":["Evidence-based medicine versus personalized medicine when attempting to block complement in IgA nephropathy"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0153-3795","authenticated-orcid":false,"given":"Giuseppe","family":"Castellano","sequence":"first","affiliation":[{"name":"Unit of Nephrology, Dialysis and Renal Transplantation, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico , Milano ,","place":["Italy"]},{"name":"Department of Clinical Sciences and Community Health, University of Milan , Milano ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Stravalaci","sequence":"additional","affiliation":[{"name":"Unit of Nephrology, Dialysis and Renal Transplantation, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico , Milano ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6684-2524","authenticated-orcid":false,"given":"Manuel A","family":"Podest\u00e0","sequence":"additional","affiliation":[{"name":"Unit of Nephrology, Dialysis and Renal Transplantation, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico , Milano ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9567-6713","authenticated-orcid":false,"given":"Francesca","family":"Zanoni","sequence":"additional","affiliation":[{"name":"Unit of Nephrology, Dialysis and Renal Transplantation, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico , Milano ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"2026073104464516300_bib1","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1056\/NEJMoa2410316","article-title":"Alternative complement pathway inhibition with iptacopan in IgA nephropathy","volume":"392","author":"Perkovic","year":"2025","journal-title":"N Engl J Med"},{"key":"2026073104464516300_bib2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2600743","article-title":"Iptacopan in IgA nephropathy\u2014final 24-month data","author":"Barratt","year":"2026","journal-title":"N Engl J Med"},{"key":"2026073104464516300_bib3","doi-asserted-by":"publisher","first-page":"16001","DOI":"10.1038\/nrdp.2016.1","article-title":"IgA nephropathy","volume":"2","author":"Lai","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"2026073104464516300_bib4","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1056\/NEJMoa2512133","article-title":"Sibeprenlimab in IgA nephropathy\u2014interim analysis of a phase 3 trial","volume":"394","author":"Perkovic","year":"2025","journal-title":"N Engl J Med"},{"key":"2026073104464516300_bib5","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1056\/NEJMoa2510198","article-title":"Atacicept in IgA nephropathy\u2014phase 3 ORIGIN trial results","volume":"394","author":"Lafayette","year":"2025","journal-title":"N Engl J Med"},{"key":"2026073104464516300_bib6","volume-title":"Fabhalta (iptacopan) capsules: US prescribing information, including boxed warning for serious infections caused by encapsulated bacteria and the Fabhalta Risk Evaluation and Mitigation Strategy (REMS)","year":"2024"},{"key":"2026073104464516300_bib7","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1093\/ndt\/gfaf200","article-title":"In situ assessment of glomerular C3\/C5 convertases indicates ongoing complement activation in IgA nephropathy","volume":"41","author":"Obrecht","year":"2026","journal-title":"Nephrol Dial Transplant"},{"key":"2026073104464516300_bib8","doi-asserted-by":"publisher","first-page":"5338","DOI":"10.3390\/jcm13175338","article-title":"C4d is an independent predictor of kidney failure in primary IgA nephropathy","volume":"13","author":"Zagorec","year":"2024","journal-title":"J Clin Med"},{"key":"2026073104464516300_bib9","doi-asserted-by":"publisher","first-page":"sfae395","DOI":"10.1093\/ckj\/sfae395","article-title":"Urine complement-related proteins in IgA nephropathy and IgA vasculitis nephritis: possible biomarkers of disease activity","volume":"18","author":"Nurmi","year":"2025","journal-title":"Clin Kidney J"},{"key":"2026073104464516300_bib10","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1038\/s41588-023-01422-x","article-title":"Genome-wide association analyses define pathogenic signaling pathways and prioritize drug targets for IgA nephropathy","volume":"55","author":"Kiryluk","year":"2023","journal-title":"Nat Genet"},{"key":"2026073104464516300_bib11","article-title":"ARTEMIS-IgAN phase 3 interim analysis: narsoplimab did not meet the primary proteinuria endpoint; trial discontinued","volume-title":"Annual Report (Form 10-K)","author":"Omeros Corporation","year":"2024"},{"key":"2026073104464516300_bib12","first-page":"25","article-title":"Proposal to withdraw approval of TAVNEOS (avacopan) capsule, 10 mg; opportunity for a hearing","volume":"91","author":"U.S. Food and Drug Administration. ChemoCentryx, Inc.","year":"2026","journal-title":"Fed Regist"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfag159\/68708015\/gfag159.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfag159\/68708015\/gfag159.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T08:46:55Z","timestamp":1785487615000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article\/doi\/10.1093\/ndt\/gfag159\/8726158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":12,"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfag159","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"article-number":"gfag159"}}